mia.burns
EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
Based upon Ongoing Femoral Nerve Block Trial, sNDA Submission Still Planned ...
barbara.lempert
Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company’s Audit Committee
PHILADELPHIA, July ...
barbara.lempert
VALCHLOR(TM) gel under FDA Review for Early-Stage Mycosis Fungoides-Type CTCL
ALLSCHWIL/BASEL, SWITZERLAND and MALVERN, PA – 31 July 2013 – Actelion US ...
barbara.lempert
—Extends Patent Life to 2030 for Novel Agent that Demonstrated Rapid Onset, Robust Efficacy and Good Safety in a Phase II Trial— EVANSTON, IL – July 30, ...
barbara.lempert
IntelligentMDx (privately held) announced today that the U.S. Food and Drug Administration (FDA) has cleared its automated molecular diagnostic test that detects the ...
Tracy Staton
As if GlaxoSmithKline didn't have enough trouble on its hands, Moody's Investors Service has cast some dark clouds over its credit outlook. The agency cut the outlook ...
mia.burns
David S. Herron Joins BioClinica to Lead Imaging Core Lab Division
– Heads World’s Largest, Most Experienced Imaging Core Lab Operations –
NEWTOWN, PA, July ...
barbara.lempert
OTTAWA, Canada, July 26, 2013 (CANADIAN PRESS DATAFILE) – A class-action lawsuit against pharmaceutical giant Pfizer Canada over its anti-smoking drug ...
barbara.lempert
NEW YORK, July 26, 2013 (AP) — Two drug companies said Friday that they hope to start selling a generic version of the multiple sclerosis treatment Copaxone ...
Ryan McBride
Five Prime Therapeutics wants to follow more than two dozen other drug developers this year onto the public market. The South San Francisco-based biotech, a developer of ...
Ryan McBride
FierceBiotech News
mia.burns
GlaxoSmithKline has replaced the British head of its Chinese operations, which are at the centre of a pounds 320m cash and sexual bribery scandal.
Britain’s ...